Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| NVCT | 8-K | bullish | 7/10 | Nuvectis Pharma reported Q2 2026 results highlighting a transformative in-licensing of ciprocopan (NXP100) and NXP200 fr | Aug 4, 2026 |
| LSTA | 8-K | bearish | 7/10 | Lisata Therapeutics slashed ~72% of its workforce, terminated its CMO, and disclosed a lawsuit against merger counterpar | Aug 4, 2026 |
| EOLS | 8-K | neutral | 4/10 | Evolus expanded its partnership with Symatese to exclusively commercialize the Estyme injectable HA gel portfolio in Can | Aug 4, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.7 | Aug 4, 2026 |
| HRMY | PRESS-RELEASE | bullish | 6/10 | Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted | Aug 4, 2026 |
| LPCN | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 4, 2026 |
| WLKP | 8-K | neutral | 4/10 | Westlake Chemical Partners LP reported Q2 2026 EPS of $0.40, a 2.4% miss vs the $0.41 consensus, while net income attrib | Aug 4, 2026 |
| PVLA | 8-K | neutral | 5/10 | Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52 per share, missing the consensus estimate of $-1 | Aug 4, 2026 |
| WLK | 8-K | bullish | 6/10 | Westlake Corp reported Q2 2026 results with a significant turnaround: net income of $260M ($2.01 EPS) vs a net loss of $ | Aug 4, 2026 |
| IBRX | 8-K | neutral | 5/10 | ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth c | Aug 4, 2026 |
| FTH | 8-K | neutral | 3/10 | Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net l | Aug 4, 2026 |
| RYTM | 8-K | bullish | 7/10 | Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.7 | Aug 4, 2026 |
| ODTX | 8-K | neutral | 4/10 | Odyssey Therapeutics reported Q2 2026 financial results with a GAAP net loss of $52.8M, wider than the $41.2M loss in Q2 | Aug 4, 2026 |
| GRTX | 8-K | bearish | 8/10 | Galera Therapeutics completed its merger with Obsidian Therapeutics (formerly Gazelle Parent) on August 3, 2026, becomin | Aug 4, 2026 |
| LNTH | 8-K, DEFA14A | bullish | 8/10 | Lantheus (LNTH) has entered into a definitive merger agreement with Curium US Holdings LLC, a private equity-backed radi | Aug 4, 2026 |
| ABVC | 8-K | neutral | 3/10 | ABVC BioPharma postponed the previously announced distribution of BioKey (Cayman) Inc. ordinary shares, which had been s | Aug 4, 2026 |
| XRTX | 6-K | neutral | 3/10 | XORTX Therapeutics filed a 6-K announcing the resignation of Anthony Giovinazzo from the board of directors for personal | Aug 4, 2026 |
| CRVO | PRESS-RELEASE | bullish | 4/10 | CervoMed announced that neflamapimod, its oral small-molecule candidate for dementia with Lewy bodies (DLB), has been gr | Aug 4, 2026 |
| TRDA | CLUSTER | neutral | 4/10 | Two insiders at Entrada Therapeutics (Director Kush Parmar and 10% owner 5AM Ventures) sold a combined $1.59M in open-ma | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes executives (EVP CLO and EVP R&D/CMO) sold a combined $536K in open-market shares on August 3, 2026, one wee | Aug 3, 2026 |
| ALKS | CLUSTER | neutral | 3/10 | Two Alkermes insiders (EVP R&D/CMO and EVP/CLO) sold a combined $536K in open-market shares on August 3, 2026, one week | Aug 3, 2026 |
| PGEN | CLUSTER | neutral | 2/10 | Precigen insiders (CFO and COO) sold a combined $826K in open-market sales over a 4-day window. The CFO sold $606K at $6 | Aug 3, 2026 |
| KLRS | 3 | neutral | 2/10 | Laurie Keating filed a Form 3 initial statement of beneficial ownership with Kalaris Therapeutics, along with a Power of | Aug 3, 2026 |
| KROS | 8-K | neutral | 4/10 | Keros Therapeutics reported Q2 2026 results with a net loss of $28.7M ($1.45/share), slightly narrower than the $30.7M l | Aug 3, 2026 |
| CYCN | 425 | neutral | 4/10 | Korsana Biosciences announced three senior leadership appointments (CMO, CTO, and a new Board member/Audit Chair) and re | Aug 3, 2026 |
| SUPN | DEFA14A, 425 | bullish | 7/10 | Supernus and Indivior announced an all-stock merger of equals to create a combined CNS biopharma company with ~$2.2B in | Aug 3, 2026 |
| STOK | 8-K | bearish | 6/10 | Stoke Therapeutics filed a prospectus supplement to sell up to $200 million of common stock in an at-the-market (ATM) of | Aug 3, 2026 |
| ARQT | 144 | neutral | 2/10 | Director Patrick Burnett filed a Form 144 notice of intent to sell 955 shares of Arcutis Biotherapeutics common stock, v | Aug 3, 2026 |
| APGE | DEFA14A | bullish | 5/10 | Apogee filed supplementary proxy materials (DEFA14A) on August 3, 2026, updating stockholders ahead of the August 11 spe | Aug 3, 2026 |
| SUPN | 8-K | bullish | 7/10 | Supernus Pharmaceuticals and Indivior have entered into an all-stock merger of equals, announced via employee communicat | Aug 3, 2026 |